Predictors for identifying the efficacy of systemic steroids on sustained exhaled nitric oxide elevation in severe asthma

Allergology International

Volumn 62, Issue 3, 2013, Pages 359-365

  Matsunaga, Kazuto ^a   Hirano, Tsunahiko ^a   Akamatsu, Keiichiro ^a   Minakata, Yoshiaki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Airflow limitation; Airway inflammation; Eosinophils; Inhaled corticosteroid

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; PREDNISOLONE; GLUCOCORTICOID; NITRIC OXIDE;

ADULT; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; EOSINOPHIL; EOSINOPHIL COUNT; EXHALED NITRIC OXIDE FRACTION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY TRACT PARAMETERS; TREATMENT RESPONSE; AGED; BLOOD; CLINICAL TRIAL; LEUKOCYTE COUNT; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ASTHMA; EOSINOPHILS; FEMALE; GLUCOCORTICOIDS; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NITRIC OXIDE; PREDNISOLONE; SEVERITY OF ILLNESS INDEX;

EID: 84884338963     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.12-OA-0530     Document Type: Article

References (30)

1. Barnes PJ, Pederson S, Busse WW. Efficacy and safety of inhaled corticosteroids. Am J Respir Crit Care Med 1998; 157:S1-53.
2. Dweik RA, Boggs PB, Erzurum SC et al, and American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline. Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602-15.
3. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993;6:1368-70.
4. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998;53:91-5.
5. Szefler SJ, Martin RJ. Lessons learned from variation in response to therapy in clinical trials. J Allergy Clin Immunol 2010;125:285-92.
6. Little SA, Chalmers GW, MacLeod KJ, McSharry C, Thomson NC. Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. Thorax 2000;55:232-4.
7. Pijnenburg MW, Bakker EM, Lever S, Hop WC, De Jongste JC. High fractional concentration of nitric oxide in exhaled air despite steroid treatment in asthmatic children. Clin Exp Allergy 2005;35:920-5.
8. Perez-de-Llano LA, Carballada F, Castro Anon O et al. Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma. Eur Respir J 2010;35:1221-7.
9. Dweik RA, Sorkness RL, Wenzel S et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 2010;181:1033-41.
10. Matsunaga K, Yanagisawa S, Hirano T et al. Associated demographics of persistent exhaled nitric oxide elevation in treated asthmatics. Clin Exp Allergy 2012;42:775-81.
11. Gelb AF, Flynn Taylor C, Shinar CM, Gutierrez C, Zamel N. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest 2006;129: 1492-9.
12. Michils A, Baldassarre S, Van Muylem A. Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients. Eur Respir J 2008;31:539-46.
13. van Veen IH, Ten Brinke A, Sterk PJ et al. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 2008;32:344-9.
14. Ohkura N, Fujimura M, Tokuda A, Furusho S, Abo M, Katayama N. Evaluation of airway hyperresponsiveness and exhaled nitric oxide as risk factors for airway remodeling in patients with stable asthma. Allergy Asthma Proc 2009;30:419-23.
15. Sugiura H, Komaki Y, Koarai A, Ichinose M. Nitrative stress in refractory asthma. J Allergy Clin Immunol 2008; 121:355-60.
16. Silkoff PE, Lent AM, Busacker AA et al. Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol 2005;116: 1249-55.
17. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. "Refractory" eosinophilic airway inflammation in severe asthma. Am J Respir Crit Care 2004;170:601-5.
18. Barnes PJ, Adock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009;373:1905-17.
19. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Updated 2011. Available at: http:www.ginasthma.org.
20. Proceedings of the American Thoracic Society Workshop on Refractory Asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000;162:2341-51.
21. Akamatsu K, Matsunaga K, Sugiura H et al. Improvement of airflow limitation by fluticasone propionate salmeterol in chronic obstructive pulmonary disease: What is the specific marker? Front Pharmacol 2011;2:36.
22. Hirano T, Kunugi A, Ichinose M. [A comparison of a new compact stationary FENO analyzer with portable hand-held device]. Kokyu [Respiration Research] 2009;28: 753-8 (in Japanese).
23. Matsunaga K, Hirano T, Kawayama T et al. Reference ranges for exhaled nitric oxide fraction in healthy Japanese adult population. Allergol Int 2010;59:363-7.
24. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005;99: 553-8.
25. Matsunaga K, Kawabata H, Hirano T, Sugiura H, Minakata Y, Ichinose M. Difference in time-course of improvement in asthma control measures between budesonide and budesonide formoterol. Pulm Pharamcol Ther 2013;26:189-94.
26. del Pozo V, de Arruda-Chaves E, de Anders B et al. Eosinophils transcribe and translate messenger RNA for inducible nitric oxide synthase. J Immunol 1997;158:859-67.
27. Thomazzi SM, Ferreira HH, Conran N, de Nucci G, Antunes E. Role of nitric oxide on in vitro human eosinophill migration. Biochem Pharmacol 2001;62:1417-21.
28. van Veen IH, Sterk PJ, Schot R, Gauw SA, Rabe KF, Bel EH. Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. Eur Respir J 2006; 27:951-6.
29. Matsunaga K, Akamatsu K, Miyatake A, Ichinose M. Natural history and and risk factors of obstructive changes over a 10-year period in severe asthma. Respir Med 2013;107:355-60.
30. Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicenter, double-blind, placebo-controlled trial. Lancet 2012;380: 651-9.